Mantle cell lymphoma (MCL) is an aggressive form of B-cell non-Hodgkin's lymphoma, with a mean survival of only 3-5 years and suboptimal therapeutic options. MCL is characterized by a balanced translocation t(11;14)(q13;q32), resulting in overexpression of cyclin D1, a G 1 cyclin regulated by the PI3K/Akt/mammalian target of rapamycin (mTOR) signaling pathway. As improved therapy for MCL is required and the mTOR pathway may be involved in its pathophysiology, the antiproliferative effects of RAD001 (everolimus), an mTOR inhibitor, against three MCL cell lines were investigated. As a single agent, RAD001 inhibited proliferation in MCL cell lines (Jeko1, SP49 and NCEB1) approximately 40-65% compared to diluent control cells. This was associated with G 1 cell-cycle arrest and reduced phosphorylation of the mTOR downstream target, 4E-BP1. Furthermore, combination drug studies revealed predominantly synergistic cytotoxicity with RAD001 and several secondary agents, including doxorubicin, vincristine or rituximab (components of the standard MCL regimen), as well as paclitaxel, vorinostat and bortezomib. These data indicate that single agent RAD001 is effective in inhibiting growth of MCL cells in vitro and combination studies with secondary agents further demonstrate synergistic cytotoxicity. Thus, these findings support future clinical studies of RAD001 in the treatment of MCL.
Introduction
Mantle cell lymphoma (MCL) is an aggressive form of B-cell non-Hodgkin's lymphoma (NHL) comprising approximately 5-10% of all NHL. Patients with MCL are predominantly male, often diagnosed in the sixth decade of life and typically present with advanced stage III or IV lymphoma with frequent involvement of the bone marrow, peripheral blood and other extranodal sites. Their mean survival is less than 5 years. 1 A distinguishing hallmark of MCL is the balanced translocation t(11;14)(q13;q32), 2 resulting in overexpression of cyclin D1. 3, 4 CCND1 is a member of the G 1 cyclins, which plays a key regulatory role in controlling cell-cycle progression. Cyclin D1 binds and activates cyclin-dependent kinases (CDK). This cyclin D1-CDK complex in turn binds and hyperphosphorylates the tumor suppressor protein, retinoblastoma (RB), which prevents it from negatively regulating crucial transcription factors, consequently allowing the cell to progress through the G 1 checkpoint into S-phase. 5, 6 Thus, overexpression of cyclin D1 observed in MCL results in a decreased G 1 -phase and premature transition of cells into the S-phase. 3 Treatment of MCL remains suboptimal and therapeutic regimens currently available to patients do not significantly increase mean survival. In recent years, focus on the mammalian target of rapamycin (mTOR) signaling for cancer therapy has intensified. 7 mTOR, a serine/threonine kinase, is a downstream target of the phosphatidylinositol 3-kinase (PI3K) and protein kinase B (Akt/PKB) pathway and has a critical role in cell survival and proliferation. Activation of PI3K/Akt and subsequent phosphorylation of mTOR initiate the phosphorylation of important downstream targets, including ribosomal p70S6 serine/threonine kinase (S6K1) and eukaryotic initiation factor (EIF)-4E binding protein (4E-BP1), resulting in an increase in mRNA translation and cap-dependent protein synthesis, respectively. 8 Identification of deregulation of the mTOR signaling pathway in types of several cancers 9 has furthered the interest in the mTOR inhibitor rapamycin (a macrolide antibiotic) and its derivatives CCI-779 and RAD001 (everolimus). Rapamycin, CCI-779 and RAD001 bind the FK506-binding protein-12 (FKBP12) and interact with mTOR, inhibiting its phosphorylation activities and halting the translation of proteins critical for proliferation and cell survival. 10 Several reports have demonstrated the anti-tumor activity of CCI-779 and RAD001 in a variety of cancers, including brain, prostate, pancreas, breast and various leukemias and lymphomas. [11] [12] [13] [14] [15] In view of the poor survival rate of patients with MCL and promising results observed with mTOR inhibitors in several cancers, this study evaluated the effect of RAD001 on MCL cells. We have demonstrated a marked inhibition of proliferation that is a direct result of RAD001 treatment and identified synergistic cytotoxicity of RAD001 with doxorubicin, vincristine or rituximab (components of standard MCL therapy), as well as paclitaxel, bortezomib and vorinostat (suberolyanilide hydroxamic acid, SAHA). These promising results warrant additional inquiries of RAD001 as a potential new treatment for MCL.
Materials and Methods

Cell culture
NCEB1 and Jeko1 (kindly provided by Dr Sven de Vos, University of California, Los Angeles) and SP49 (generous gift of Dr Daibata, Kochi University, Japan) cell lines were established from MCLs and maintained in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) supplemented with 20% fetal bovine serum (FBS), 10 U/ml penicillin and 10 mg/ml streptomycin (P/S) (Invitrogen) at 371C in 5% CO 2 . U937 acute monocytic leukemia (AMoL), HL60 acute myeloblastic leukemia (AML) and K562 erythroid blast crisis of chronic myeloid leukemia (CML) cell lines (purchased from American Type Culture Collection, Manassas, VA, USA) were maintained under similar conditions in RPMI 1640 supplemented with 10% FBS and P/S.
MTT proliferation assays and isobologram analysis
Cells were treated with either dimethyl sulfoxide (DMSO) diluent control or various concentrations of RAD001 (everolimus; kindly provided by The Novartis Institutes for BioMedical Research Basel, Oncology, Switzerland) in the presence or absence of chemotherapy reagents. Based on preliminary dose-response assays, doxorubicin hydrochloride (Adriamycin), vincristine (Oncovin), rituximab (Rituxan), paclitaxel (Taxol), bortezomib (Velcade) and vorinostat (kindly provided by Dr VM Richon, Merck & Co., Whitehouse Station, NJ, USA) were freshly diluted in growth media and immediately added to cells along with RAD001. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich, St. Louis, MO, USA) was performed as previously described. 16 Cytotoxic interactions of RAD001 with other agents were evaluated by isobologram (CalcuSyn software, Biosoft, Cambridge, UK 
Western blot analysis
With either RAD001 or DMSO diluent control 1 Â 10 6 cells/ml were treated with either RAD001 or DMSO diluent control and incubated for 24 h at 371C. Total cell lysates were prepared in lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1.0 mM EDTA, 1.0% NP-40, 0.25% sodium deoxycholate, with a protease inhibitor cocktail (Roche Molecular Biochemicals, Germany), resolved with a 4-15% gradient SDS-polyacrylamide (PAGE) gel (BioRad Laboratories, Hercules, CA, USA), transferred to a polyvinylidene fluoride membrane (Pall Corporation Life Sciences, Ann Arbor, MI, USA) and probed with the following antibodies: anti-4E-BP1, anti-phospho-4E-BP1 (Thr37/ 46), eIF4E antibodies (Cell Signaling Technology, Beverly, MA, USA) and anti-b-actin antibody (Sigma-Aldrich). Blots were developed using the Supersignal West Pico chemiluminescent substrate (Pierce Biotechnology, Rockford, IL, USA).
4EBP1-eIF4E association assay
With either RAD001 or DMSO diluent control 1 Â 10 6 cells/ml were treated with either RAD001 or DMSO diluent control and incubated for 24 h at 371C. Total cell lysates were prepared in lysis buffer including protease inhibitor cocktail and 450 mg of protein was incubated with 25 ml 7-methyl-GTP Sepharose (Amersham Biosciences, Piscataway, NJ) overnight on a rotator at 41C. Lysates were then washed several times with PBS and Western blot analysis was performed as described above.
Cell-cycle analysis
With RAD001 2.5 Â 10 6 cells/ml were treated with RAD001 and incubated for 24 h at 371C. Cells were washed with cold PBS, fixed with methanol, incubated on ice for 30 min and analysis was performed by flow cytometry (FACScan, Becton Dickinson, Franklin Lakes, NJ, USA).
Results
The effects of RAD001 on cell proliferation of human hematopoietic cell lines were examined by MTT assay. Under nutrient-poor conditions or mTOR inhibition, 4E-BP1 tightly binds eIF4E. This interaction inhibits eIF4E association with eIF4A/eIF4G, and subsequent formation of the multifunctional eIF4F complex and cap-dependent translation. 8 After 24 h incubation with 2000 nM RAD001, Jeko1, SP49 and NCEB1 lysates were evaluated for eIF4E and 4E-BP1 expression. RAD001 treatment did not have an impact on overall eIF4E expression (Figures 2b-d , middle panels), but did result in increased 4E-BP1-eIF4E interaction in RAD001-treated cells compared to diluent-treated control cells (Figures 2b-d, top  panels) . This phenomenon was observed in all three MCL cell lines. Additionally, Jeko1, SP49 and NCEB1 cells were incubated with RAD001 (20 and 2000 nM for 24 h) and cellcycle analysis was performed. An inhibition of cell-cycle progression occurred as a direct result of RAD001 treatment, as demonstrated by an increased proportion of cells in the G 0 -G 1 and decreased percentage in the S phase in all three MCL cell lines (Figure 3 ).
Our data demonstrate that RAD001 efficiently inhibits mTOR activity in MCL cells in vitro, as established by decreased cell proliferation, lower levels of phosphorylation of the downstream target 4E-BP1 with enhanced 4E-BP1-eIF4E interaction, and G 1 cell-cycle arrest. Given the poor prognosis of MCL and our encouraging results with RAD001, we investigated further the potential beneficial interactions of RAD001 with existing chemotherapy currently utilized for MCL and other hemato- Cell lysates were prepared and association of 4E-BP1 and eIF4E was determined using 7-methyl-GTP Sepharose assay. Treatment with RAD001 did not identify any differences in eIF4E expression (middle panels). However, 4E-BP1 expression increased in all three cell lines treated with RAD001, indicative of an enhanced 4E-BP1-eIF4E association (top panels). For loading control, western blots were stripped and re-probed with b-actin (bottom panels). RAD001 effects on mantle cell lymphoma T Haritunians et al poietic disorders. 18, 19 Dose-response experiments for various chemotherapy reagents were conducted with each of our MCL cell lines to identify the optimal concentrations for combination drug studies (data not shown).
Jeko1, SP49 and NCEB1 cells were cultured for 96 h with 2.0-2000 nM RAD001 in combination with varying concentrations of a secondary agent. We evaluated the effects of either doxorubicin (Table 1a) or vincristine (Figure 4a and Table 1b) , components of a standard MCL chemotherapy regimen, in combination with RAD001. We chose a dose of doxorubicin that caused, approximately, 10-30% proliferation inhibition (data not shown). Results obtained with doxorubicin and RAD001 combination studies suggest predominantly synergistic interactions for all cell lines evaluated (Table 1a) . (Figure 4a and Table 1b) .
Current standard MCL regimens include standard cytotoxic agents, doxorubicin and vincristine, in combination with rituximab, an anti-CD20 monoclonal antibody. 20 Although rituximab monotherapy has been shown to yield modest results, combination chemotherapy plus rituximab has demonstrated more promising effects. 21, 22 Thus, we chose to evaluate the combined activity of RAD001-rituximab therapy on our MCL cell lines. Although we did not observe any antiproliferative effects against NCEB1 and Jeko1 in response to rituximab treatment, SP49 cells cultured with rituximab exhibited approximately 30% inhibition of proliferation (Figure 4b, left panel) . Additionally, our studies identified that the combination of RAD001 and 10 mg/ml rituximab produced very strong synergistic effects (CI values o0.1) with all RAD001 doses (2-2000 nM) evaluated (Figure 4b ).
Encouraged by the potential synergistic activity observed with RAD001 and vincristine in Jeko1 cells, we also evaluated effects of RAD001 in the presence of paclitaxel, another compound affecting microtubules. Similar to our studies with other drugs, we chose a concentration of paclitaxel that alone induced a moderate inhibition of proliferation (approximately 10-30%) of the MCL cells (data not shown). Combination studies in SP49 and NCEB1 cells identified synergism with 5 nM paclitaxel and all RAD001 concentrations evaluated. However, Jeko1 cells revealed synergistic interactions when treated with 2.5 nM paclitaxel in combination with either 20 or 200 nM RAD001, while paclitaxel and 2000 nM RAD001 identified an additive interaction (Table 1c) .
Jeko1, SP49 and NCEB1 were also treated with either bortezomib (Velcade, a proteosome inhibitor) or vorinostat (SAHA, a histone deacetylase inhibitor). Once again, we selected a bortezomib dose, which yielded approximately 10-15% inhibition of proliferation in all three cell lines (data not shown) and produced predominantly synergistic interactions when in combination with nearly all RAD001 doses evaluated (Table 1e) . Similarly, we chose a dose of vorinostat that produced a moderate inhibition (approximately 15-20%) for Jeko1 cells (data not shown), and our combination studies consistently identified very strong synergistic interactions, with CI values below 0.1 (Table 1d ). Although it was necessary to use a higher dose of vorinostat for SP49 cells (yielding approximately 60% inhibition of proliferation in our dose-response experiments) (data not shown), similar strong synergism (CIp0.2) was, nevertheless, identified with all RAD001 doses (2-2000 nM) evaluated (Table 1d) .
Discussion
MCL is an incurable, aggressive form of B-cell NHL exhibiting rapid disease progression and poor overall survival. 23, 24 
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Identification of dysregulation of the PI3K/Akt and downstream mTOR pathways in MCL and several other cancers has focused increased attention in recent years on potential therapeutic advantages of mTOR inhibitors. 25, 26 In preliminary experiments, we have found the PI3K/Akt/mTOR pathway to be activated in MCL cells, as measured by enhanced phosphorylation of these proteins (Kawamata N et al., unpublished data). Standard therapeutic regimens for MCL include a combination of the chemotherapy drugs cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or cyclophosphamide, vincristine and prednisone (CVP). 27 In recent years, studies have investigated the benefits of a chimeric anti-CD20 antibody, rituximab, in combination with standard chemotherapy. 28 Unfortunately, the higher response rates observed with rituximab in combination with CHOP therapy did not translate into prolonged progressionfree survival. 22, 29 However, combination therapies of CHOP/CVP, rituximab and total body irradiation, followed by autologous stem cell transplantation, have demonstrated an improvement in complete remission and overall survival rates. 21, 30 MCL is characterized by a balanced translocation t(11;14)(q13;q32) and overexpression of cyclin D1, 4 a G 1 cyclin regulated by the PI3K/Akt/mTOR signaling pathway. 31 Studies have presented encouraging results utilizing the mTOR inhibitor rapamycin and its derivatives in various hematological malignancies and solid tumors, [11] [12] [13] [14] [15] 32 with one recent report identifying substantial anti-tumor activity in MCL. 33 Witzing et al. 33 conducted a phase II trial of CCI-779 in thirty-four patients with either relapsed or refractory MCL and identified an overall response rate of 38%, without significant toxicity.
In light of recent promising reports of RAD001 treatment in various leukemias/lymphomas 13, 17, 19, 32, 34 and given the necessity for improved therapeutic options for MCL, we chose to focus our studies on this specific lymphoma subtype. Our data revealed considerable antiproliferative effects in response to RAD001 treatment in Jeko1, SP49 and NCEB1 MCL cell lines (Figure 1a) . Furthermore, the antiproliferative effects observed in these MCL cells correlated with an increased proportion of cells in G 0 -G 1 and a concomitant decrease in the number of cells in S-phase (Figure 3 ). Rapamycin and RAD001 have previously been shown similarly to induce G 1 cell-cycle arrest in Hodgkin's lymphoma, anaplastic large-cell lymphoma and MCL, as well as, AML cell lines. 13, 34, 35 Annexin V apoptosis studies did not identify any significant changes in the percentage of apoptotic cells following treatment with RAD001 (data not shown). Additionally, our MTT proliferation assays demonstrated inhibition of proliferation of U937 and HL60 AML and K562 CML cell lines (Figure 1b) , in agreement with a recent study demonstrating rapamycin sensitivity of these cell lines. 13 Interestingly, 20 nM of RAD001 gave near-maximal inhibition with little additional antiproliferative effects at 200 and 2000 nM (Figure 1 ). This observation has also been described by Sun et al. 36 who suggested that it represented a subset of cells that are resistant to the effects of RAD001.
Treatment with 20 and 2000 nM RAD001 revealed a distinct and dose-dependent decrease in phosphorylated 4E-BP1, a downstream target of mTOR, in all three MCL cell lines ( Figure  2a , top panel) We also found that treatment with RAD001 resulted in enhanced levels of 4E-BP1 expression in comparison to eIF4E (Figures 2b-d) , indicative of an enhanced 4E-BP1-eIF-4E association. 37 This interaction appears to be rapamycin sensitive, as rapamycin-resistant cells exhibit reduced binding of 4E-BP1 to eIF-4E. 
Having established the antiproliferative activities of single agent RAD001, we were interested to identify potentially beneficial interactions between RAD001 and available chemotherapeutic drugs. Initially, our combination studies included doxorubicin and vincristine, components of the CHOP chemotherapy cocktail widely used to treat MCL. Anthracyclines, such as doxorubicin, are cytotoxic antibiotics that interfere with proper cell division by disrupting DNA structure, while vincristine, a vinca alkaloid, disrupts microtubule formation and inhibits mitosis. Our results demonstrated predominantly synergistic interactions between RAD001 and doxorubicin for all the cell lines (Table 1a ). Rapamycin has recently been shown to enhance doxorubicin-induced apoptosis in acute lymphoblastic leukemia cells. 32 RAD001 and vincristine combination studies also identified synergism for all cell lines, with very strong synergistic effects observed with SP49 and Jeko1 cells (Figure 4a and Table 1b) . Of interest will be to evaluate further the potential interactions between RAD001 and other vinca alkaloids currently in clinical use, such as vinblastine, vindesine and vinorelbine.
Encouraged by our results from the RAD001-vincristine combination studies, we additionally examined RAD001-paclitaxel interactions. Low-dose administration of paclitaxel has been reported to be a well-tolerated, less toxic alternative for patients with aggressive NHL. 39 Like vincristine, paclitaxel interferes with proper cell division. However, while vincristine inhibits microtubule formation, paclitaxel binds microtubules, interfering with their depolymerization and disassembly of the mitotic spindle. Our studies revealed promising synergistic interactions for the RAD001-paclitaxel combination in all cell lines tested (Table 1c) .
Several studies have recently demonstrated the benefits of rituximab treatment in combination with standard CHOP chemotherapy. 40 Phase III clinical trials conducted by Lenz et al. 22 demonstrated 94% overall response rate and 34% complete remission with CHOP-rituximab (CHOP-R) therapy, in comparison with 75% overall response and 7% remission observed with CHOP treatment alone. They also observed an increase in time to treatment failure with CHOP-R (21 versus 14 months). Additional studies have reported 27-48% response rates with CHOP-R chemoimmunotherapy. 29, 41 Unfortunately, these responses did not translate into significant differences in long-term progression-free survival between CHOP and CHOP-R. 22, 29 Only one MCL cell line, SP49, demonstrated antiproliferative effects in response to rituximab; however, all RAD001 doses evaluated revealed strong antiproliferative synergism against these cells (Figure 4b ).
Vorinostat is a histone deacetyltransferase (HDAC) inhibitor that exhibits significant antiproliferative effects against a variety of human lymphoid cancer cell lines, including MCL cells. 42 Furthermore, the PI3K/Akt/mTOR pathway appears to be activated in MCL (Kawamata N et al., unpublished data). Although we were not able to obtain informative data for NCEB1 cells treated with RAD001 plus vorinostat, combination studies with our other two MCL cell lines (Jeko1 and SP49) identified synergistic interactions with all RAD001 doses (Table 1d) .
Bortezomib is a potent and reversible proteosome inhibitor that modulates nuclear factor-kappa B (NF-kB). NF-kB plays a crucial role in cell-cycle regulation and apoptosis and is known to be involved in the pathogenesis of many cancers, including MCL. 43, 44 In vitro studies have revealed inhibition of constitutive NF-kB activation and cyclin D1 expression, as well as, G 1 cell-cycle arrest and enhanced apoptosis in MCL cell lines treated with bortezomib. 43 Furthermore, bortezomib is well tolerated with minimal toxicity and clinical trials have demonstrated encouraging results in NHL, with overall response rates of 41% for MCL and 19-58% for other NHL. [45] [46] [47] Additionally, RAD001 has recently been shown to inhibit NF-kB. 34 Thus, we evaluated the combined effects of RAD001 with bortezomib and observed predominantly synergistic interactions with all three MCL cell lines (Table 1e) .
Although standard therapeutic regimens may enhance the quality of life for months, they have not been able to have a major impact on survival rates, emphasizing the necessity for additional therapeutic options. This study identifies growth inhibitory effects in vitro of RAD001 alone and significant synergistic interactions when combined with existing chemotherapeutic drugs. The findings presented here suggest that the combination of RAD001 with other effective agents may greatly increase the efficiency of therapy for MCL.
